

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

1. (original) A method of recovering factor VIII/vWF-complex, characterized in that factor VIII/vWF-complex from a protein solution is bound to a cation exchanger and is recovered by step-wise elution of factor VIII/vWF-complex, which particularly contains high-molecular vWF-multimers.

2-16. (canceled)

17. (currently amended) An isolated protein fraction comprising a FactorVIII/vWF-complex containing low molecular vWF multimers, non-complexed or weakly bound factor VIII and free factor VIII, Factor VIII:C, substantially free from platelet agglutinating vWF activity, obtainable obtained from a factor VIII/vWF-containing solution by cation exchange chromatography and step-wise elution at a salt concentration of between $\geq 200\text{mM}$ and $\leq 300\text{mM}$, wherein the factor VIII/vWF-containing solution is a cryoprecipitate, or a supernatant or extract of a recombinant cell culture.

18. (withdrawn) A preparation comprising factor VIII:C as set forth in claim 17, wherein said preparation is virus safe and free from infectious material.

19. (withdrawn) A preparation as set forth in claim 18, wherein said preparation is present in storage-stable form.

20. (withdrawn) A preparation as set forth in claim 18, wherein said preparation is formulated as a pharmaceutical preparation.

21. (withdrawn) A method of treating patients suffering from at least one of hemophilia A, phenotypic hemophilia and vWD, comprising administering to said patients an

effective dose of a factor VIII/vWF-complex having specific vWF activity of at least 66 U/mg protein and a specific factor VIII activity of at least 500 U/mg protein, wherein said factor VIII/vWF-complex is virus safe and free from infectious material.

22. (withdrawn) A method of treating patients suffering from at least one of hemophilia A, phenotypic hemophilia and vWF, comprising administering to said patients an effective dose of the factor VIII:C of claim 17.